New antibody drug aims to tame Hard-to-Treat kidney disease

NCT ID NCT07234474

Not yet recruiting Disease control Sponsor: Excyte Biopharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys. The main goals are to check safety and how the drug behaves in the body, with a preliminary look at whether it might help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YK012 (a bispecific antibody that targets B cells and T cells to reduce immune attack on the kidneys)
What this could lead to: If it works, this could point toward a new treatment option for people with a severe, hard-to-treat kidney disease that has not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The drug may cause side effects or fail to improve kidney function. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MEMBRANOUS NEPHROPATHY

More trials for these conditions

Other studies related to the condition(s) this trial covers.